QTTB Stock Analysis: Buy, Sell, or Hold?
QTTB - Q32 Bio Inc. Common Stock
$15.68
0.12 (0.77%)
▲
5d:
+3.5%
30d:
+24.44%
90d:
+180.0%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When QTTB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: QTTB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: QTTB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: QTTB is currently trading at $15.68, which is considered slightly high relative to its 30-day fair value range of $12.61 to $16.67.
Technical Outlook: Technically, QTTB is in a strong uptrend. Immediate support is located at $14.13, while resistance sits at $16.61.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (24th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.50 (+183.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, QTTB is in a strong uptrend. Immediate support is located at $14.13, while resistance sits at $16.61.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (24th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.50 (+183.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$12.61 -
$16.67
Company Quality Score
54/100
(HOLD)
Options IV Signal
24th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Options cheap (IV 24th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 183.8% below Wall St target ($44.50)
Trading Range Analysis
30-Day Trading Range
$12.61 -
$16.67
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$2.45
(15.6%)
Support & Resistance Levels
Support Level
$14.13
Resistance Level
$16.61
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.04
Wall Street Target
$44.50
(+183.8%)
Profit Margin
61.9%
Share & Embed Analysis
Last updated: August 03, 2026 1:02 AM ET
Data refreshes hourly during market hours. Next update: 2:02 AM
Data refreshes hourly during market hours. Next update: 2:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QTTB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jodie Pope Morrison
SELL
9896 shares
2026-02-25
Lee Kalowski
SELL
3995 shares
2026-02-25
Shelia M Violette
SELL
2815 shares
2026-02-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 46 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 54 HOLD |
